Pulmonology

Monitoring Your Progress and Daily Support

At a Glance

RA-ILD monitoring combines changes in breathing symptoms, pulmonary function tests such as FVC and DLCO, and selected HRCT scans. Worsening in at least two areas over 12 months may indicate progressive pulmonary fibrosis and prompt a treatment review.

Living with RA-ILD means entering a phase of “active monitoring.” Because the disease can change over time, your medical team will not just treat you once and stop; they will look for specific markers of progression to decide if your treatment needs to be adjusted ^[1]^[2].

Tracking Your Progress

Doctors use three main “lenses” to see if your lung disease is moving forward. This is often done at intervals that are “clinically appropriate”—meaning they are tailored to how you are feeling and how stable your previous tests were ^[3].

Symptom Review: The most important indicator is often how you feel. A significant increase in shortness of breath or a worsening cough over 12 months is a key sign of progression ^[4]^[5].
Physiologic Testing (PFTs): Your FVC (lung volume) and DLCO (oxygen transfer) are the “vital signs” of your ILD ^[6]. Small fluctuations are normal, but consistent declines are concerning ^[7].
Radiologic Imaging (HRCT): While you won’t need a CT scan at every visit, a repeat scan is used to look for physical changes in the lung tissue, such as increased scarring or new areas of inflammation ^[4]^[8].

What is “Progressive Pulmonary Fibrosis”?

You may hear your doctor use the term Progressive Pulmonary Fibrosis (PPF). This is a specific framework used to identify when the disease is demonstrating a progressive fibrotic phenotype. Under current international guidelines, PPF is defined as meeting at least two of the following criteria within a 12-month period, provided there is no better alternative explanation ^[4]^[5]:

Worsening Symptoms: A noticeable increase in respiratory symptoms ^[4].
Physiologic Decline: An absolute drop of at least 5 percentage points in your FVC percent-predicted or at least 10 percentage points in your DLCO percent-predicted ^[4]. (Note: some studies use a 10% relative drop in FVC as the threshold instead ^[2]).
Radiologic Progression: Increased scarring (fibrosis), honeycombing, or “traction bronchiectasis” (stretched airways) visible on an HRCT scan ^[4]^[9].

A decline in tests should prompt a thorough clinical review to ensure changes aren’t driven by anemia, infection, or heart disease.

Supportive Care: What You Can Do

While medications do the heavy lifting of calming the immune system, “supportive care” focuses on protecting the lung tissue you have and improving your quality of life ^[10].

Smoking Cessation: This is perhaps the most critical step you can take. Smoking is linked to a higher risk of RA-ILD, more frequent “acute exacerbations,” and a higher risk of mortality ^[11]^[12]. Quitting helps reduce the constant irritation that triggers the immune system in your lungs ^[13].
Pulmonary Rehabilitation: This is a structured program that includes exercise training, nutritional advice, and breathing techniques ^[10]. While it doesn’t “fix” the scarring, it trains your muscles to use oxygen more efficiently, which can significantly reduce how short of breath you feel during daily tasks ^[14].
Supplemental Oxygen: If your oxygen levels drop too low—either at rest, during sleep, or while exercising—your doctor may prescribe supplemental oxygen ^[15]. Using oxygen as prescribed can reduce the strain on your heart and help you stay more active ^[10].
Infection Protection: Because the treatments for RA-ILD suppress your immune system, staying current on vaccinations (like the flu and pneumonia shots) is a vital part of your ongoing care ^[16]^[17].

Monitoring is not just about looking for bad news; it is about gathering the data needed to make sure you are on the most effective treatment plan possible ^[18].

Common questions in this guide

What tests are used to monitor RA-ILD?

Clinicians usually combine symptom reviews, pulmonary function tests, and sometimes high-resolution CT scans. FVC measures how much air you can breathe out, while DLCO estimates how well oxygen moves from your lungs into your blood. The timing of testing is tailored to your symptoms and previous results.

What does progressive pulmonary fibrosis mean in RA-ILD?

Progressive pulmonary fibrosis, or PPF, describes a pattern in which lung scarring worsens over time. It is generally identified when at least two of worsening breathing symptoms, a meaningful decline in FVC or DLCO, or increasing scarring on a high-resolution CT scan occur within 12 months, with no better explanation.

What FVC or DLCO changes can suggest RA-ILD progression?

Guidelines use an absolute drop of at least 5 percentage points in FVC percent predicted or at least 10 percentage points in DLCO percent predicted as physiologic evidence of PPF. Some studies use a relative 10% decline in FVC instead. Your clinician should interpret the trend and rule out anemia, infection, or heart disease.

Can pulmonary rehabilitation help people with RA-ILD?

Yes. Pulmonary rehabilitation combines exercise training, breathing techniques, and nutritional advice. It does not remove lung scarring, but it can help your muscles use oxygen more efficiently and reduce breathlessness during daily activities.

When might someone with RA-ILD need supplemental oxygen?

A clinician may prescribe supplemental oxygen if oxygen levels fall too low at rest, during sleep, or with exercise. Using oxygen as prescribed can reduce strain on the heart and help you remain active.

How does smoking affect rheumatoid arthritis-associated lung disease?

Smoking is linked with a higher risk of RA-ILD, more frequent acute flare-ups, and a higher risk of death. Quitting reduces ongoing irritation in the lungs, and counseling or nicotine replacement may make quitting easier.

Get notified when new evidence is published on rheumatoid arthritis-associated interstitial lung disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Heterogeneity of Rheumatoid Arthritis-Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes.
England BR, Yang Y, Roul P, et al.
Arthritis care & research 2026; (78(2)):249-258 doi:10.1002/acr.25620.
PMID: 40771150
2
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality.
Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E
Respiration; international review of thoracic diseases 2019; (98(5)):455-460 doi:10.1159/000502551.
PMID: 31597131
3
Development of a prediction model for progression of rheumatoid arthritis-associated interstitial lung disease using serologic and clinical factors: The prospective KORAIL cohort.
Chang SH, Paudel ML, McDermott GC, et al.
Seminars in arthritis and rheumatism 2025; (73()):152729 doi:10.1016/j.semarthrit.2025.152729.
PMID: 40294559
4
Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.
Naqvi M, Hannah J, Lawrence A, et al.
Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.
PMID: 39039699
5
Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Chang SH, Park YB, McDermott GC, et al.
The Journal of rheumatology 2025; (52(4)):323-333 doi:10.3899/jrheum.2024-0713.
PMID: 39814449
6
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Johnson SR, Bernstein EJ, Bolster MB, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(8)):1201-1213 doi:10.1002/art.42860.
PMID: 38973714
7
Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease.
El Husseini K, Lee JS, Juge PA, et al.
The European respiratory journal 2025; (66(6)) doi:10.1183/13993003.00587-2025.
PMID: 40967766
8
The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease.
Abu Qubo A, Capaccione KM, Bernstein EJ, et al.
Frontiers in medicine 2021; (8()):679051 doi:10.3389/fmed.2021.679051.
PMID: 35096848
9
A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis.
Li L, Gao S, Fu Q, et al.
Clinical rheumatology 2019; (38(11)):3169-3178 doi:10.1007/s10067-019-04673-4.
PMID: 31302858
10
Management issues in rheumatoid arthritis-associated interstitial lung disease.
England BR, Hershberger D
Current opinion in rheumatology 2020; (32(3)):255-263 doi:10.1097/BOR.0000000000000703.
PMID: 32141954
11
Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.
Samhouri BF, Vassallo R, Achenbach SJ, et al.
Arthritis care & research 2022; (74(12)):2042-2049 doi:10.1002/acr.24856.
PMID: 34995017
12
Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M, Zhu C, Ye Y
BMC pulmonary medicine 2023; (23(1)):255 doi:10.1186/s12890-023-02532-2.
PMID: 37434169
13
Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis.
Johnson C, Giles JT, Bathon J, et al.
PloS one 2016; (11(4)):e0153024 doi:10.1371/journal.pone.0153024.
PMID: 27050433
14
Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.
Huang S, Kronzer VL, Dellaripa PF, et al.
Current treatment options in rheumatology 2020; (6(4)):337-353 doi:10.1007/s40674-020-00160-z.
PMID: 33282632
15
Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes.
Nurmi HM, Purokivi MK, Kärkkäinen MS, et al.
BMC pulmonary medicine 2016; (16(1)):107 doi:10.1186/s12890-016-0269-2.
PMID: 27461264
16
Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.
Mueller KT, Saavedra AA, O'Keeffe LA, Sparks JA
Drugs & aging 2025; (42(2)):81-94 doi:10.1007/s40266-024-01175-0.
PMID: 39800810
17
The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.
Wang Y, Chen S, Zheng S, et al.
Arthritis research & therapy 2021; (23(1)):212 doi:10.1186/s13075-021-02586-9.
PMID: 34391465
18
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
Atienza-Mateo B, Fernández-Díaz C, Vicente-Rabaneda EF, et al.
European journal of internal medicine 2024; (119()):118-124 doi:10.1016/j.ejim.2023.08.025.
PMID: 37673775

This page is for informational purposes only and does not constitute medical advice. Ask your respiratory and rheumatology team to interpret your RA-ILD tests and decide on oxygen, rehabilitation, vaccinations, or treatment changes.

Guide Contents